Journavx™

Drug - Journavx™ (suzetrigine) [Vertex Pharmaceuticals, Inc.]

July 2025

Therapeutic Area - Neuropathic pain and select agents

Approval criteria

Age ≥ 18 years; AND
Patient has moderate to severe acute pain, as confirmed by a pain score or rating system (e.g. numeric pain rating scale NPRS], verbal categorical rating scale [VRS]); AND
Journavx will be used for the shortest duration consistent with individual patient treatment goals and will NOT be used beyond 14 days; AND
Patient is NOT taking a strong cytochrome P450 (CYP) 3A inhibitor (e.g., itraconazole, grapefruit juice); AND
Patient is NOT taking a moderate or strong CYP3A inducer (e.g., rifampin, carbamazepine, St. John’s Wort); AND
Patient does NOT have severe hepatic impairment (Child-Pugh Class C); AND
Patients taking hormonal contraceptives containing progestins other than levonorgestrel and norethindrone will use additional nonhormonal contraceptives (e.g., condoms) or alternative contraceptives (e.g., combined oral contraceptive containing ethinyl estradiol and levonorgestrel or norethindrone; intrauterine system) during treatment and for 28 days after discontinuation.

Provider Call Center (844) 575-7887